SCHEMBL2514931

SCHEMBL2514931

O=C(Oc1cnccn1)c1ccccc1.[Rh]

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.50
LMNA P02545 6/20 0.50
HSD17B10 Q99714 1/20 0.50
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.45
METAP2 P50579 1/20 0.44
METAP1 P53582 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
ALDH1A1 P00352 4/20 0.43
MAPT P10636 3/20 0.43
F2 P00734 1/20 0.42
ATM Q13315 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
APP P05067 1/20 0.42
GAA P10253 1/20 0.42
HCAR3 P49019 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30336754 0.98 KMT2A (0.51) KMT2ALMNAHSD17B10TSHRSMN1; SMN2
SCHEMBL2514952 0.98 KMT2A (0.51) KMT2ALMNAHSD17B10TSHRSMN1; SMN2
SCHEMBL27479651 0.89 TSHR (0.48) KMT2ALMNAHSD17B10TSHRSMN1; SMN2
SCHEMBL20298354 0.87 ALDH1A1 (0.57) KMT2ALMNATSHRSMN1; SMN2ALDH1A1
SCHEMBL28996119 0.86 HSD17B10 (0.56) KMT2ALMNAHSD17B10TSHRSMN1; SMN2
SCHEMBL15573500 0.83 KMO (0.47) KMT2ALMNAHSD17B10TSHRSMN1; SMN2
SCHEMBL15572574 0.83 KMO (0.47) KMT2ALMNAHSD17B10TSHRSMN1; SMN2
SCHEMBL15572594 0.83 KMO (0.47) KMT2ALMNAHSD17B10TSHRSMN1; SMN2
SCHEMBL15572964 0.83 KMO (0.47) KMT2ALMNAHSD17B10TSHRSMN1; SMN2
SCHEMBL2829058 0.79 LMNA (0.53) KMT2ALMNATSHRSMN1; SMN2METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1914263-B1 SINGLE-CRYSTALLINE ORGANIC CARBOXYLIC ACID METAL COMPLEX, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF UNIV YOKOHAMA CITY (JP) 2012-12-05 EP disclosed
US-8034165-B2 Single-crystalline organic carboxylic acid metal complex, process for producing the same, and use thereof YOKOHAMA CITY UNIVERSITY (JP) 2011-10-11 US disclosed
US-20090139401-A1 Single-crystalline organic carboxylic acid metal complex, process for producing the same, and use thereof YOKOHAMA CITY UNIVERSITY (JP) 2009-06-04 US disclosed
EP-1914263-A1 SINGLE-CRYSTALLINE ORGANIC CARBOXYLIC ACID METAL COMPLEX, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF Yokohama City University (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090139401-A1 Single-crystalline organic carboxylic acid metal complex, process for producing the same, and use thereof CA1, CA3, CA12 KMT2A 1948/4885LMNA 4756/4885HSD17B10 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.